REVVITY, INC.

Our fiscal year ends on the Sunday nearest December 31. We report fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. The fiscal year ending January 3, 2027 (“fiscal year 2026”) will include 53 weeks, and the fiscal year ended December 28, 2025 (“fiscal year 2025”) included 52 weeks.

We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

The principal products and services of our two reportable segments are:

•Life Sciences. Provides products and services targeted towards life sciences customers.

•Diagnostics. Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the areas of reproductive health, immunodiagnostics and emerging market diagnostics.

Overview of the Third Quarter of Fiscal Year 2026

Our overall revenue in the third quarter of fiscal year 2026 was $728.9 million which increased by $30.0 million, or 4%, as compared to the third quarter of fiscal year 2025, reflecting an increase of $36.8 million, or 11%, in our Life Sciences segment revenue, and a decrease of $6.8 million, or 2%, in our Diagnostics segment revenue. The increase in our Life Sciences segment revenue for the third quarter of fiscal year 2026 was driven by an increase in both Life Sciences Solutions and Software business. The decrease in our Diagnostics segment revenue for the third quarter of fiscal year 2026 was driven by a decrease in our Immunodiagnostics business partially offset by an increase in our Reproductive Health business.

Our consolidated gross margins increased 380 basis points from 53.6% to 57.4% in the third quarter of fiscal year 2026, as compared to the third quarter of fiscal year 2025, primarily due to favorable product mix shift and restructuring benefit. Our consolidated operating margins increased 130 basis points from 11.7% to 13.1% in the third quarter of fiscal year 2026, as compared to the third quarter of fiscal year 2025, primarily due to improvements in gross margins and cost productivity partially offset by restructuring charges.